Compare Pfizer Inc (PFE) vs Prudential PLC (PUK) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

Prudential (PUK) trades at $28.88, up 2.09% today, showing strong fundamental momentum with revenue growth from $16.21B in 2024 to $27.4B projected for 2025 and consistent earnings beats. The stock appears undervalued with a P/E of 9.21 and P/S of 1.34, while technical indicators show a bearish trend despite neutral oscillators. Recent news highlights JP Morgan's positive catalyst watch ahead of August earnings and strategic moves in Asian markets.

The outlook remains positive given strong profitability (21.15% ROE) and analyst support (50% buy ratings), but risks include regulatory challenges in Japan and China exposure. Current valuation metrics suggest potential upside if earnings momentum continues, though technical resistance near $29 may limit near-term gains.